Scottish Medical Journal最新文献_第9页

Integrated bioinformatic analysis of key biomarkers and signalling pathways in psoriasis. 银屑病关键生物标志物和信号通路的综合生物信息学分析。

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 Epub Date: 2022-02-11 DOI: 10.1177/00369330221078993

Suwei Tang, Wencheng Jiang, Ping Xu, Shaoqiong Xie, Mingxia Wang, Chunjie Gao, Jiajing Lu, Yang Yang

{"title":"Integrated bioinformatic analysis of key biomarkers and signalling pathways in psoriasis.","authors":"Suwei Tang, Wencheng Jiang, Ping Xu, Shaoqiong Xie, Mingxia Wang, Chunjie Gao, Jiajing Lu, Yang Yang","doi":"10.1177/00369330221078993","DOIUrl":"10.1177/00369330221078993","url":null,"abstract":"Background and aims: Psoriasis is a relatively common autoimmune inflammatory skin disease with a chronic etiology. Since psoriasis is still incurable, it is necessary to identify the molecular mechanisms of psoriasis. The present study was designed to detect novel biomarkers and pathways associated with psoriasis incidence, and provide new insights into treatment of psoriasis.Methods and results: Differentially expressed genes (DEGs) associated with psoriasis in the Gene Expression Omnibus (GEO) database were identified, and their functional roles and interactions were then annotated and evaluated through GO, KEGG, and gene set variation (GSVA) analyses. In total 197 psoriasis-related DEGs were identified and found to primarily be associated with the NOD-like receptor, IL-17, and cytokine-cytokine receptor interaction signalling pathways. GSVA revealed significant differences between normal and lesional groups (P < 0.05), while PPI network analyses identified CXCL10 as the hub gene with the highest degree value, whereas IRF7, IFIT3, OAS1, GBP1, and ISG15 were promising candidate genes for the therapeutic treatment of psoriasis.Conclusion: The findings of the present integrated bioinformatics may enhance our understanding of the molecular events occurring in psoriasis, and these candidate genes and pathways together may prove to be therapeutic targets for psoriasis.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"67 1","pages":"7-17"},"PeriodicalIF":2.7,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39909767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Scottish Paediatric Society St Andrew's Day Paediatic Symposium 2020. 2020年苏格兰儿科学会圣安德鲁日儿科研讨会

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 DOI: 10.1177/00369330211068774

引用次数: 0

ABSTRACT SUBMISSION - Autumn Meeting - 29 October 2021. 提交摘要-秋季会议-2021年10月29日

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 DOI: 10.1177/00369330221074572

引用次数: 0

Scottish Paediatric Society Summer Meeting 2021. 苏格兰儿科学会2021年夏季会议

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 DOI: 10.1177/00369330211068776

引用次数: 0

A clinical trial comparing BiVap (Richard Wolf®) saline vaporization of the prostate vs. Twister^TM Diode Laser System in the treatment of benign prostatic obstruction between prostate volume 90 to 150 ml. 一项比较BiVap (Richard Wolf®)前列腺生理盐水汽化与TwisterTM二极管激光系统治疗前列腺容积90 ~ 150ml良性前列腺阻塞的临床试验。

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 Epub Date: 2021-12-31 DOI: 10.1177/00369330211072262

Ayhan Karakose, Yasin Yitgin

{"title":"A clinical trial comparing BiVap (Richard Wolf®) saline vaporization of the prostate vs. TwisterTM Diode Laser System in the treatment of benign prostatic obstruction between prostate volume 90 to 150 ml.","authors":"Ayhan Karakose, Yasin Yitgin","doi":"10.1177/00369330211072262","DOIUrl":"https://doi.org/10.1177/00369330211072262","url":null,"abstract":"Introduction: To evaluate the efficacy, safety and postoperative outcomes of the BiVap and Twister systems with benign prostatic obstruction (BPO) in prostate volüm between 90-150 ml.Methods: In total, we included 131 patients treated with BiVap system (n = 68) and Twister system (n = 63). Postoperative complications including urinary tract infection, transient hematuria, severe dysuria and fever >38° C, urinary incontinence and urethral stricture were also noted. All patients were evaluated at the postoperative 1st, 3rd, 6th and 12th month and preoperative and postoperative values of IPSS score, QoL score, total PSA, IIEF 15, PVR, Qmax and Qave were compared.Results: Preoperative demographic characteristics were similar in the 2 groups. There was observed significant improvement for IPSS, Qmax, Qave, PVR, and QoL score by the postoperative first month compared to the preoperative values in both groups. Maximum improvement in the IPSS, Qmax, Qave, QoL score and PVR were achieved at postoperative 6, 3, 12, 3 and 12th months respectively in group 1. In group 2 maximum improvement in the same parameters were achieved at postoperative 6, 3, 6, 6 and 12th months, respectively.Conclusions: BiVap and Twister systems are safe, effective, and useful technique, which can be used in the surgical treatment of BPO between 90-150 ml.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"67 1","pages":"38-45"},"PeriodicalIF":2.7,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39652081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Learning from the report of the independent medicines and medical devices safety review: "first do no harm". 从独立药品和医疗器械安全审查报告中学习:“首先做到无危害”。

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 Epub Date: 2022-01-07 DOI: 10.1177/00369330211058467

Priyanka H Krishnaswamy, Marie-Anne Ledingham, Veenu Tyagi, Karen Lesley Guerrero

{"title":"Learning from the report of the independent medicines and medical devices safety review: \"first do no harm\".","authors":"Priyanka H Krishnaswamy, Marie-Anne Ledingham, Veenu Tyagi, Karen Lesley Guerrero","doi":"10.1177/00369330211058467","DOIUrl":"https://doi.org/10.1177/00369330211058467","url":null,"abstract":"This is a review of the learning points from the Independent Medicines and Medical Devices Safety Review,1 chaired by Baroness Julia Cumberlege CBE DL. This system-wide review was initiated by the then Secretary of State for Health and Social Care, following patient-led campaigns. It looked at how the \"healthcare system reacted as a whole, and how that response can be made more robust, speedy and appropriate\".We aim to highlight the learning points for doctors in Obstetrics and Gynaecology as these are relevant to our current practice and future changes in our healthcare system. These are: Aims of the review: why it was initiated and how it was conductedOverarching themes and missed opportunities to prevent avoidable harmThree clinical scenarios: their histories, issues and adverse events associated with their use and the current response in Scotland The hormone pregnancy test - PrimodosThe anti-epileptic drug - sodium valproateSurgical mesh for prolapse & incontinenceThe recommendations made by the review and implementation guidanceResponses to the review, such as apologies issued by BSUG2/BAUS3/RCOG,4 and compensations schemes such as the Scottish scheme as recommended by the review.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"67 1","pages":"2-6"},"PeriodicalIF":2.7,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39795358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Devices and Procedures Regulation in Medical Practice: Is There a Need for More transparency? 医疗实践中的器械和程序监管：是否需要提高透明度？

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 DOI: 10.1177/00369330221080789

Ghulam Nabi

引用次数: 0

Abstracts for Research & Audit Presentation - 12th November 2021. 研究和审计报告摘要- 2021年11月12日

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2022-02-01 DOI: 10.1177/00369330211068775

引用次数: 0

Waist circumference, hip circumference, arm span, and waist-to-hip ratio high risk of polycystic ovarian syndrome. 腰围、臀围、臂跨、腰臀比多囊卵巢综合征高危人群。

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2021-11-01 Epub Date: 2021-10-18 DOI: 10.1177/00369330211043206

Tazkia Mawaddatina, Uki Retno Budihastuti, Dwi Rahayu

{"title":"Waist circumference, hip circumference, arm span, and waist-to-hip ratio high risk of polycystic ovarian syndrome.","authors":"Tazkia Mawaddatina, Uki Retno Budihastuti, Dwi Rahayu","doi":"10.1177/00369330211043206","DOIUrl":"https://doi.org/10.1177/00369330211043206","url":null,"abstract":"Background and aims: Polycystic ovarian syndrome is a reproductive problem of women with high prevalence cases accompanied by obesity conditions. Obesity condition can be seen from the size of waist circumference, hip circumference, arm span, and waist-to-hip ratio. This study aims to find out the risk factors between waist circumference size, hip circumference, arm span, and waist-to-hip ratio with polycystic ovarian syndrome.Methods: This research is an analytical observation using a case-control approach conducted at Sekar Fertility Clinic and Poly Obgyn Dr Moewardi General Hospital Surakarta. Subjects were 150 consisting of 75 polycystic ovarian syndrome women and 75 normal fertile women. Sampling techniques used in this study are purposive sampling, researchers doing anthropometric measurements in the form of waist circumference, hip circumference, arm span, and waist-to-hip ratio simultaneously. The results were analyzed using Statistic Product and Service Solution 25.Results: The results of the study obtained waist circumference with polycystic ovarian syndrome (b = 3.002; CI 95% = 3.41-123.5; p = 0.001), hip circumference (b = -2.671; CI 95% = 0.01-0.37; p = 0.002), arm span (b = 5.318; CI 95% = 32.23-129.58; p < 0.001) and waist-to-hip ratio (b = 1.761; CI 95% = 1.02-33.01; p = 0.047).Conclusion: Waist circumference size, hip circumference, arm span, and waist-to-hip ratio correlate to a high risk of polycystic ovarian syndrome. Arm span is more dominant as an indicator of high risk to polycystic ovarian syndrome compared to waist circumference, hip circumference, and waist-to-hip ratio.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"66 4","pages":"186-190"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39553220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

National trends and cost of litigation in UK National Health Service (NHS): a specialty-specific analysis from the past decade. 英国国家医疗服务体系(NHS)的国家趋势和诉讼费用:过去十年的专项分析。

IF 2.7 4区医学

Scottish Medical Journal Pub Date : 2021-11-01 DOI: 10.1177/00369330211052627

Jenni Lane, Rahul Bhome, Bhaskar Somani

{"title":"National trends and cost of litigation in UK National Health Service (NHS): a specialty-specific analysis from the past decade.","authors":"Jenni Lane, Rahul Bhome, Bhaskar Somani","doi":"10.1177/00369330211052627","DOIUrl":"https://doi.org/10.1177/00369330211052627","url":null,"abstract":"Background and aims: Medical litigation claim and costs in UK are rising. This study aims to analyse the 10-year trend in litigation costs for individual clinical specialties in the UK from 2009/10 to 2018/19.Methods: Data were procured from National Health Service (NHS) Resolution. Number of claims, total litigation costs and cost per claim were ascertained for each financial year. The data collected also includes the number of claims and average amount per claim per speciality during the years 2009-2019 (2009/2010 to 2018/2019 financial years).Results: The total annual cost of NHS litigation is currently £3.6 billion(2018/2019). Damages make up the greatest proportion of costs(£1.5 billion). Surgical specialties have the greatest number of claims annually(2847) but Obstetrics has the greatest total litigation(£1.9 billion) and cost per claim(£2.6 million). Number of claims, total costs and cost per claim are significantly greater in 2018/2019 than in 2009/2010.Conclusions: Addressing the issue of litigations is complex. Medically there are speciality specific issues that require attention, whilst some general measures are common to all: effective communication, setting realistic targets and maintaining a motivated, adequately staffed workforce. These, alongside legal reforms, may reduce the financial burden of increasing litigation on the NHS.","PeriodicalId":21683,"journal":{"name":"Scottish Medical Journal","volume":"66 4","pages":"168-174"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39849685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17